<DOC>
	<DOCNO>NCT00475501</DOCNO>
	<brief_summary>The purpose study determine whether higher-than-replacement dose testosterone finasteride combine safely increase muscle strength old men low blood concentration testosterone .</brief_summary>
	<brief_title>5-Alpha Reductase Anabolic Effects Testosterone</brief_title>
	<detailed_description>Approximately 40 % old male veteran low serum testosterone concentration . The latter associate diminished muscle strength bone mineral density , depress mood , low pain tolerance , frailty , increased mortality . Replacement dose testosterone administer hypogonadal men purpose reverse deficit muscle bone . Although testosterone clearly important maintain muscle bone men , problem associate T replacement . First , testosterone cause number undesired effect , include fluid retention , gynecomastia , worsen sleep apnea , polycythemia , prostate enlargement acceleration early-stage prostate cancer . The anabolic effect obtain date testosterone replacement relatively modest , especially old men . Our hypothesis combine treatment higher-than-replacement dose testosterone 5- reductase inhibitor produce substantial anabolic effect , prevent testosterone-induced prostate enlargement possibly adverse effect . We plan investigate efficacy safety combine treatment testosterone finasteride old hypogonadal male veteran conduct 12-month randomize , placebo-controlled trial . We administer higher-than-replacement dose testosterone plus 5- reductase inhibitor finasteride group hypogonadal , otherwise healthy old men . We determine whether treatment safe effective mean increase muscle mass strength . Men age 60 80 , circulate total testosterone 300 ng/dL bioavailable testosterone 70 ng/dL , treat 125 mg testosterone enanthate/week 5 mg finasteride/day 1 year . We assess effect body composition , 1- repetition maximum ( 1-RM ) strength , grip strength , functional reach , bone mineral density , mood , cognition , hematopoiesis prostate volume . We choose moderately high dose testosterone may cause adverse effect . We predict finasteride block anabolic effect testosterone , block prostate enlargement symptom possibly adverse effect well .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Sarcopenia</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Eunuchism</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Finasteride</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Anabolic Agents</mesh_term>
	<criteria>Age &gt; 60 year males Primary care Malcolm Randall VA Medical Center Gainesville , Florida . Consenting subject morning ( 6:00 AM 10:00 AM ) serum total testosterone 300 ng/dL bioavailable testosterone concentration 70 ng/dL exclusion criterion randomize receive either testosterone placebo . Subjects cognitive impairment identify MiniCog test exclude . The MiniCog high sensitivity specificity cognitive impairment , affect level education . We also exclude subject receptive aphasia , contraindication testosterone replacement ( i.e. , history active prostate breast cancer , severe benign prostatic hyperplasia assess elevated American Urologic Association Symptom Index ( AUASI ) score &gt; 25 ) , congestive heart failure ( Class 3 4 ) , sleep apnea syndrome , polycythemia ( Hct &gt; 55 % ) , prostate specific antigen ( PSA ) &gt; 2.6 ng/mL ) exclude . Obese subject ( BMI &gt; 35 ) also exclude . Subjects currently receive testosterone supplementation subject allergy testosterone also exclude . Subjects previously receive testosterone replacement therapy must medication least four week .</criteria>
	<gender>Male</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>anabolic effect</keyword>
	<keyword>finasteride</keyword>
	<keyword>male hypogonadism</keyword>
	<keyword>sarcopenia</keyword>
	<keyword>testosterone</keyword>
</DOC>